LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Cell

• Publication date

  2016-10-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ccell.2016.09.007PMID 27728807
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo

  2016cited by this paper
• Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.

  2016cited by this paper
• Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

  2016cited by this paper
• Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression.

  2016cited by this paper
• Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study

  2015cited by this paper
• Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A.

  2015cited by this paper
• Mutations driving CLL and their evolution in progression and relapse

  2015cited by this paper
• Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

  2014cited by this paper
• B Cell–Specific Loss of Lyn Kinase Leads to Autoimmunity

  2014cited by this paper
• Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

  2014cited by this paper
• Chronic Lymphocytic Leukemia Cells in a Lymph Node Microenvironment Depict Molecular Signature Associated with an Aggressive Disease

  2014cited by this paper
• Sensitizing protective tumor microenvironments to antibody-mediated therapy.

  2014cited by this paper
• Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

  2014cited by this paper
• Cortactin, another player in the Lyn signaling pathway, is over-expressed and alternatively spliced in leukemic cells from patients with B-cell chronic lymphocytic leukemia

  2014cited by this paper
• Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy.

  2014cited by this paper
• Lyn-mediated procaspase 8 dimerization blocks apoptotic signaling in B-cell chronic lymphocytic leukemia.

  2014cited by this paper
• Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

  2014cited by this paper
• How will B-cell-receptor-targeted therapies change future CLL therapy?

  2014cited by this paper
• A critical role for Lyn kinase in strengthening endothelial integrity and barrier function.

  2013cited by this paper
• B cell receptor signaling in chronic lymphocytic leukemia.

  2013cited by this paper
• Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies.

  2013cited by this paper
• The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation

  2013cited by this paper
• IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.

  2013cited by this paper
• Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor.

  2013cited by this paper
• Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo

  2013cited by this paper
• Hyperactivated MyD88 signaling in dendritic cells, through specific deletion of Lyn kinase, causes severe autoimmunity and inflammation

  2013cited by this paper
• Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia.

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers.

  2013cited by this paper
• CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia.

  2013cited by this paper
• Targeting pathological B cell receptor signalling in lymphoid malignancies

  2013cited by this paper
• Phosphatidylinositol‐3 kinase activity in B cells is negatively regulated by Lyn tyrosine kinase

  2012cited by this paper
• Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells.

  2012cited by this paper
• Functions of the Lyn tyrosine kinase in health and disease

  2012cited by this paper
• Yes and Lyn play a role in nuclear translocation of the Epidermal Growth Factor Receptor

  2012cited by this paper
• Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia.

  2012cited by this paper
• Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia

  2012cited by this paper
• Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia.

  2012cited by this paper
• The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

  2011cited by this paper
• Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

  2011cited by this paper
• LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer.

  2010cited by this paper
• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

  2010cited by this paper
• PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.

  2009cited by this paper
• Opposite expression pattern of Src kinase Lyn in acute and chronic haematological malignancies

  2009cited by this paper
• Molecular and cellular mechanisms of CLL: novel therapeutic approaches

  2009cited by this paper
• Multiple roles of Lyn kinase in myeloid cell signaling and function

  2009cited by this paper
• The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

  2009cited by this paper
• Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5.

  2008cited by this paper
• The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.

  2008cited by this paper
• BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.

  2007cited by this paper
• Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.

  2005cited by this paper
• Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha.

  2005cited by this paper
• Src-family kinases: rheostats of immune cell signaling.

  2004cited by this paper
• Role of the microenvironment in chronic lymphocytic leukaemia

  2003cited by this paper
• Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression

  2002cited by this paper
• The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species

  2001cited by this paper
• Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage.

  2001cited by this paper
• Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.

  2000cited by this paper
• Redundant and Opposing Functions of Two Tyrosine Kinases, Btk and Lyn, in Mast Cell Activation1

  2000cited by this paper
• Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.

  1999cited by this paper
• Independent and Opposing Roles For Btk and Lyn in B and Myeloid Signaling Pathways

  1998cited by this paper
• A critical role of Lyn and Fyn for B cell responses to CD38 ligation and interleukin 5.

  1997cited by this paper
• Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation.

  1997cited by this paper
• Activation of BTK by a Phosphorylation Mechanism Initiated by SRC Family Kinases

  1996cited by this paper
• Regulation of Btk by Src family tyrosine kinases

  1996cited by this paper
• Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice.

  1995cited by this paper
• Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease.

  1995cited by this paper
• Defective B cell development and function in Btk-deficient mice.

  1995cited by this paper
• Binding of Bruton's tyrosine kinase to Fyn, Lyn, or Hck through a Src homology 3 domain-mediated interaction.

  1994cited by this paper
• Association of B cell antigen receptor with protein tyrosine kinase Lyn.

  1991cited by this paper

• Botrychium ternatum, the Hmong medicinal flora, improves acetaminophen-induced hepatic injury by inhibiting the abnormal activation of the B cell receptor signaling pathway.

  2026cites this paper
• Single-cell transcriptomics and machine-learning reveal M1 macrophage-driven progression from minimal change disease to focal segmental glomerulosclerosis

  2026cites this paper
• Reduced CSF1R expression in myeloid cells has limited impact on chronic lymphocytic leukemia progression

  2025influential citation
• Lyn expression in macrophages promotes TLR activation and restricts proliferation in an isoform-independent manner

  2025cites this paper
• 3D Tumor microenvironment interaction reveals AP‐1 complex regulation and contact‐mediated reprogramming of bone marrow stromal cells in chronic lymphocytic leukemia

  2025cites this paper
• Total, not isoform-specific, Lyn expression by macrophages promotes TLR activation and restricts proliferation

  2025cites this paper
• Allosteric Coupling in Full-Length Lyn Kinase Revealed by Molecular Dynamics and Network Analysis

  2025cites this paper
• Therapeutic advances in chronic lymphocytic leukemia: A focus on molecular pathogenesis, targeted therapies, and supportive care.

  2025cites this paper
• Comparative analysis of macrophage feeder systems reveals distinct behaviors and key transcriptional shifts in chronic lymphocytic leukemia cells via coculture

  2025cites this paper
• Systemic MIF facilitates chronic lymphocytic leukemia development independent of its cellular source

  2025cites this paper
• Targeting SET to counteract Lyn activation demonstrates anti-cancer potential in diffuse large B-cell lymphoma

  2025cites this paper
• CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: from interconnected signalling pathways to therapeutic strategies.

  2024cites this paper
• The survival grip–how cell adhesion promotes tumor maintenance within the microenvironment

  2024cites this paper
• CD11b deficiency attenuates the ischemia/reperfusion‐induced AKI‐to‐CKD process by regulating macrophage polarization

  2024cites this paper
• Lessons learned from the Eµ-TCL1 mouse model of CLL.

  2024cites this paper
• KIRA6 is an Effective and Versatile Mast Cell Inhibitor of IgE‐mediated Activation

  2024cites this paper
• Targeting the NTSR2/TrkB oncogenic pathway in chronic lymphocytic leukemia

  2024influential citation
• B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia

  2024cites this paper
• Decoding the Tumour Microenvironment: Molecular Players, Pathways, and Therapeutic Targets in Cancer Treatment

  2024cites this paper
• Updates on the biology of chronic lymphocytic leukemia: introductory editorial.

  2024cites this paper
• Impact of leukemia-associated macrophages on the progression and therapy response of chronic lymphocytic leukemia.

  2024cites this paper
• Targeting the tumor microenvironment for treating double refractory chronic lymphocytic leukemia.

  2024cites this paper
• Nanoformulation of dasatinib cannot overcome therapy resistance of pancreatic cancer cells with low LYN kinase expression

  2024cites this paper
• Integrated signaling and transcriptome analysis reveals Src family kinase individualities and novel pathways controlled by their constitutive activity

  2023cites this paper
• Stromal cells support the survival of human primary chronic lymphocytic leukemia (CLL) cells through Lyn-driven extracellular vesicles

  2023influential citation
• Role of the tumor microenvironment in CLL pathogenesis.

  2023cites this paper
• Accelerating multiplexed profiling of protein-ligand interactions: High-throughput plate-based reactive cysteine profiling with minimal input.

  2023cites this paper
• LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1

  2023cites this paper
• The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia

  2022cites this paper
• Integrated virtual screening and MD simulation study to discover potential inhibitors of Lyn-kinase: targeting cancer therapy

  2022cites this paper
• The path to venetoclax resistance is paved with mutations, metabolism, and more

  2022cites this paper
• PKCβ Facilitates Leukemogenesis in Chronic Lymphocytic Leukaemia by Promoting Constitutive BCR-Mediated Signalling

  2022cites this paper
• Macrophage- and BCR- but not TLR-derived signals support the growth of CLL and Richter Syndrome murine models in vivo.

  2022cites this paper
• Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells

  2022cites this paper
• Protein kinase C‐β‐dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia

  2021cites this paper
• IL-9 in CLL: sensing home and settling down!

  2021cites this paper
• Towards Control Of Chronic Lymphocytic Leukemia With Targeted Agents

  2021cites this paper
• Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures

  2021cites this paper
• The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma

  2021cites this paper
• Targeting SRC Family Kinases in Mesothelioma: Time to Upgrade

  2020cites this paper
• Src Family Protein Kinase Controls the Fate of B Cells in Autoimmune Diseases

  2020cites this paper
• Relevant Cytokines in the B Cell Lymphoma Micro-Environment

  2020cites this paper
• Relation of Neutrophil Gelatinase-Associated Lipocalin Overexpression to the Resistance to Apoptosis of Tumor B Cells in Chronic Lymphocytic Leukemia

  2020cites this paper
• Meta-Analysis Reveals Significant Sex Differences in Chronic Lymphocytic Leukemia Progression in the Eµ-TCL1 Transgenic Mouse Model

  2020cites this paper
• Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice.

  2020cites this paper
• Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition

  2020cites this paper
• Lyn controls chemotaxis and motility of CLL cells via phosphorylation of ROR1

  2020cites this paper
• Erlotinib is effective against FLT3‐ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn

  2020cites this paper
• Rejection of adoptively transferred Eµ-TCL1 chronic lymphocytic leukemia cells in C57BL/6 substrains or knockout mouse lines

  2019cites this paper
• Targeted therapies in CLL. New drugs against CLL recurrent mutations

  2019cites this paper
• Updates on the hematologic tumor microenvironment and its therapeutic targeting

  2019cites this paper
• Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment

  2019cites this paper
• CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages

  2019cites this paper
• Occupational exposure to polycyclic aromatic hydrocarbons and early biomarkers related to cardiovascular disease and cancer

  2019cites this paper
• Cancer-related proteins in serum are altered in workers occupationally exposed to polycyclic aromatic hydrocarbons: a cross-sectional study

  2019influential citation
• Identification of Potential Candidate Genes of Oral Cancer in Response to Chronic Infection With Porphyromonas gingivalis Using Bioinformatical Analyses

  2019cites this paper
• New roles for B cell receptor associated kinases: when the B cell is not the target

  2019cites this paper
• Hepatocyte Growth Factor: A Microenvironmental Resource for Leukemic Cell Growth

  2019cites this paper
• Identification of key genes related to dexamethasone-resistance in acute lymphoblastic leukemia

  2018cites this paper
• The bone marrow microenvironment in health and disease at a glance

  2018cites this paper
• On the architecture of translational research designed to control chronic lymphocytic leukemia.

  2018cites this paper
• TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.

  2018cites this paper
• PI3K p110&dgr; inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression

  2018cites this paper
• Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?

  2018cites this paper
• Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib

  2018cites this paper
• Pathogenesis of CLL: the view from the lymph node

  2018cites this paper
• Towards control of chronic lymphocytic leukemia using chemotherapy-free combinations

  2018cites this paper
• Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions.

  2018cites this paper
• Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia

  2018cites this paper
• Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy

  2018cites this paper
• Targeting B cell receptor signalling in cancer: preclinical and clinical advances

  2018cites this paper
• Molecular subtyping of cancer and nomination of kinase candidates for inhibition with phosphoproteomics: Reanalysis of CPTAC ovarian cancer

  2018cites this paper
• Circular RNAs play an important role in late-stage gastric cancer: Circular RNA expression profiles and bioinformatics analyses

  2017cites this paper
• Triptonide acts as a novel potent anti-lymphoma agent with low toxicity mainly through inhibition of proto-oncogene Lyn transcription and suppression of Lyn signal pathway.

  2017cites this paper
• Mature lymphoid malignancies: origin, stem cells, and chronicity.

  2017cites this paper
• Role and timing of new drugs in CLL

  2017cites this paper
• The duality of macrophage function in chronic lymphocytic leukaemia.

  2017cites this paper
• Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro‐environmental dialogue

  2017cites this paper
• Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment

  2017cites this paper
• Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk

  2017cites this paper
• A New Role for Lyn in the CLL Microenvironment.

  2016cites this paper